Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis
Olivier Govaere, Simon Cockell, Dina Tiniakos, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 572
Open Access | Times Cited: 295

Showing 1-25 of 295 citing articles:

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 994
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.
Nature (2021) Vol. 592, Iss. 7854, pp. 450-456
Open Access | Times Cited: 891
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease
Dongdong Wang, Emily A. Day, Logan K. Townsend, et al.
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 10, pp. 592-607
Closed Access | Times Cited: 286
Current therapies and new developments in NASH
Jean‐François Dufour, Quentin M. Anstee, Elisabetta Bugianesi, et al.
Gut (2022) Vol. 71, Iss. 10, pp. 2123-2134
Open Access | Times Cited: 139
Impact of non-invasive biomarkers on hepatology practice: Past, present and future
Quentin M. Anstee, Laurent Castéra, Rohit Loomba
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1362-1378
Open Access | Times Cited: 138
Discovery of farnesoid X receptor and its role in bile acid metabolism
John Y.L. Chiang, Jessica M. Ferrell
Molecular and Cellular Endocrinology (2022) Vol. 548, pp. 111618-111618
Open Access | Times Cited: 119
CXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie, John B. G. Mackey, Thomas Jamieson, et al.
Gut (2022) Vol. 71, Iss. 10, pp. 2093-2106
Open Access | Times Cited: 110
Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis
Kazuhiro Kozumi, Takahiro Kodama, Hiroki Murai, et al.
Hepatology (2021) Vol. 74, Iss. 5, pp. 2452-2466
Open Access | Times Cited: 99
GDF15 promotes weight loss by enhancing energy expenditure in muscle
Dongdong Wang, Logan K. Townsend, Geneviève J. DesOrmeaux, et al.
Nature (2023) Vol. 619, Iss. 7968, pp. 143-150
Open Access | Times Cited: 99
Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
Marisa R. Morrow, Battsetseg Batchuluun, Jianhan Wu, et al.
Cell Metabolism (2022) Vol. 34, Iss. 6, pp. 919-936.e8
Open Access | Times Cited: 98
A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures
Olivier Govaere, Megan Hasoon, Leigh Alexander, et al.
Nature Metabolism (2023) Vol. 5, Iss. 4, pp. 572-578
Open Access | Times Cited: 65
Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice
Qian Ye, Yi Liu, Guiji Zhang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 55
Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression
Adrien Guillot, Marc Winkler, Milessa Silva Afonso, et al.
Hepatology (2023) Vol. 78, Iss. 1, pp. 150-166
Closed Access | Times Cited: 53
Immunology of human fibrosis
Mallar Bhattacharya, Prakash Ramachandran
Nature Immunology (2023) Vol. 24, Iss. 9, pp. 1423-1433
Closed Access | Times Cited: 48
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
Michèle Vacca, Ioannis Kamzolas, Lea Mørch Harder, et al.
Nature Metabolism (2024) Vol. 6, Iss. 6, pp. 1178-1196
Open Access | Times Cited: 45
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Paul Brennan, Ahmed M. Elsharkawy, Timothy J. Kendall, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 679-688
Open Access | Times Cited: 43
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Shuang Wang, Scott L. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 716
Open Access | Times Cited: 42
Molecular mechanisms in MASLD/MASH-related HCC
Xiaobo Wang, Liang Zhang, Bingning Dong
Hepatology (2024)
Closed Access | Times Cited: 27
Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease
Olivier Govaere, Sine Kragh Petersen, Nuria Martínez-López, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 5, pp. 1001-1012
Open Access | Times Cited: 95
Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis
Zhongyi Wang, Adrian Keogh, Annick Waldt, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 74
Role of bile acids in inflammatory liver diseases
Ioannis Evangelakos, Jöerg Heeren, Esther Verkade, et al.
Seminars in Immunopathology (2021) Vol. 43, Iss. 4, pp. 577-590
Open Access | Times Cited: 72
IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease
Jiwoon Park, Yuanyuan Zhao, Fan Zhang, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 1, pp. 45-56
Open Access | Times Cited: 63
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease
Aidan McGlinchey, Olivier Govaere, Dawei Geng, et al.
JHEP Reports (2022) Vol. 4, Iss. 5, pp. 100477-100477
Open Access | Times Cited: 60
Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis
Satoshi Kawamura, Yuki Matsushita, Shigeyuki Kurosaki, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 11
Open Access | Times Cited: 60
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease
Naoto Fujiwara, Naoto Kubota, Émilie Crouchet, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 650
Open Access | Times Cited: 60
Page 1 - Next Page

Scroll to top